In breast cancer screening, mammography is the gold standard. But about half of all women who follow standard screening protocol for 10 years will receive a false-positive result that will require additional screening, particularly women who have dense breast tissue, researchers said.
Used in conjunction with mammography, imaging based on nuclear medicine is currently being used as a successful secondary screening alongside mammography to reduce the number of false positive results in women with dense breasts and at higher risk for developing breast cancer, they said.
A new device called a variable angle slant hole (VASH) collimator provides all of these benefits and more.
"When used in a molecular breast imager, the device has just demonstrated in early studies to capture 3D molecular breast images at higher resolution than current 2D scans in a format that may be used alongside 3D digital mammograms," said Drew Weisenberger from Jefferson Lab.
The new device replaces a component in existing molecular breast imagers, researchers said.
While a mammogram uses X-rays to show the structure of breast tissue, molecular breast imagers show tissue function. For instance, cancer tumours are fast growing, so they gobble up certain compounds more rapidly that healthy tissue.
A radiopharmaceutical made of such a compound will quickly accumulate in tumours. A radiotracer attached to the molecule gives off gamma rays, which can be picked up by the molecular breast imager, researchers said.
Current molecular breast imaging systems use a traditional collimator, which is essentially a rectangular plate of dense metal with a grid of holes, to "filter" the gamma rays for the camera, researchers said.
The collimator only allows the system to pick up the gamma rays that come straight out of the breast, through the holes of collimator, and into the imager. This provides for a clear, well-defined image of any cancer tumours, they said.
Researchers found that using the VASH collimator with an existing breast molecular imaging system, they could get six times better contrast of tumours in the breast, which could potentially reduce the radiation dose to the patient by half from the current levels, while maintaining the same or better image quality.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
